Urovant Sciences GmbH et al v. Intas Pharmaceuticals Limited et al
| Delaware District Court | |
| Case #: | 1:25-cv-00373 |
| Nature of Suit | 835 Property Rights - Patent – Abbreviated New Drug Application |
| Cause | 35:1 Patent Infringement |
| Case Filed: | Mar 26, 2025 |
| Last checked: Friday Mar 28, 2025 1:08 AM EDT |
|
Defendant
Accord Healthcare Inc.
|
|
|
Defendant
Intas Pharmaceuticals Limited
|
|
|
Plaintiff
Sumitomo Pharma America, Inc.
|
Represented By
|
|
Plaintiff
Urovant Sciences GmbH
|
Represented By
|
| Docket last updated: 03/30/2025 11:59 PM EDT |
| Thursday, March 27, 2025 | ||
| 6 | 6
service
Summons Issued
Thu 03/27 9:30 AM
Summons Issued as to Accord Healthcare Inc. on 3/27/2025; Intas Pharmaceuticals Limited on 3/27/2025.(oam) |
|
|
Att: 1
Summons Issued
|
||
| Wednesday, March 26, 2025 | ||
| 5 | 5
misc
Disclosure Statement - Rule 7.1
Thu 03/27 9:22 AM
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Sumitomo Pharma Switzerland GmbH, Other Affiliate Sumitomo Chemical Co., Ltd., Other Affiliate Sumitomo Pharma Co., Ltd. for Urovant Sciences GmbH; Corporate Parent Sumitomo Pharma Co., Ltd., Other Affiliate Sumitomo Chemical Co., Ltd. for Sumitomo Pharma America, Inc. filed by Sumitomo Pharma America, Inc., Urovant Sciences GmbH. (oam) |
|
| 4 | 4
misc
Patent/Trademark Report to Commissioner of Patents
Thu 03/27 9:13 AM
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 12,102,638 B2. (oam) |
|
| 2 | 2
misc
Magistrate Consent Forms
Thu 03/27 9:06 AM
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (oam) |
|
| 1 | 1
13
pgs
cmp
Complaint
Thu 03/27 9:05 AM
COMPLAINT for PATENT INFRINGEMENT filed against Accord Healthcare Inc., Intas Pharmaceuticals Limited ( Filing fee $ 405, receipt number ADEDC-4646846.) - filed by Sumitomo Pharma America, Inc., Urovant Sciences GmbH.(oam) |
|
|
Att: 1
Exhibit A-B,
|
||
|
Att: 2
Civil Cover Sheet
|
||
| Thursday, March 06, 2025 | ||
| 3 | 3
misc
ANDA Form
Thu 03/27 9:12 AM
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 02/11/2025. Date of Expiration of Patent: 03/22/2040. Thirty Month Stay Deadline: 6/23/2028. (oam) |
|